Integrilin and International normalised ratio increased - a phase IV clinical study of FDA data

Summary:

International normalised ratio increased is reported as a side effect among people who take Integrilin (eptifibatide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Heparin, and have Angina unstable.

The phase IV clinical study analyzes which people have International normalised ratio increased when taking Integrilin. It is created by eHealthMe based on reports of 3,029 people who have side effects when taking Integrilin from the FDA, and is updated regularly.

What is Integrilin?

Integrilin has active ingredients of eptifibatide. eHealthMe is studying from 3,037 Integrilin users. Check the latest studies of Integrilin.

What is International normalised ratio increased?

International normalised ratio increased is found to be associated with 1,336 drugs and 1,727 conditions by eHealthMe. Check the latest studies of International normalised ratio increased.

On Jul, 29, 2026

3,029 people reported to have side effects when taking Integrilin.
Among them, 20 people (0.66%) have International normalised ratio increased.

Could Integrilin cause International normalised ratio increased?

Among these 20 people:

How long have people been on Integrilin when they have International normalised ratio increased? *

What is the gender of people who have International normalised ratio increased when taking Integrilin? *

female: 38.89 %
male: 61.11 %

What is the age of people who have International normalised ratio increased when taking Integrilin? *

What are other drugs people take besides Integrilin? *

What are other side effects people have besides International normalised ratio increased? *

Hypotension (abnormally low blood pressure): 5 people, 25.00%
Haemoglobin Decreased: 5 people, 25.00%
Cardiogenic Shock (inadequate circulation of blood): 4 people, 20.00%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 3 people, 15.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 15.00%
Bleeding Disorders: 3 people, 15.00%
Haematuria (presence of blood in urine): 3 people, 15.00%
Retroperitoneal Haemorrhage (bleeding between the peritoneum and the posterior abdominal wall): 3 people, 15.00%
Activated Partial Thromboplastin Time Prolonged: 3 people, 15.00%
Haematocrit Decreased: 2 people, 10.00%

What are the existing conditions these people have? *

Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 5.00%
Angina Unstable (chest pain due to ischemia of the heart muscle- unstable): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Integrilin and have International normalised ratio increased?

- Check whether International normalised ratio increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Integrilin:

Integrilin (3,037 reports)

International normalised ratio increased treatments and more:

International normalised ratio increased (40,071 reports)

How severe was International normalised ratio increased and when was it recovered:

International normalised ratio increased in Integrilin

Expand to all the drugs that have ingredients of eptifibatide:

International normalised ratio increased and drugs with ingredients of eptifibatide

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Integrilin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with International normalised ratio increased:

International normalised ratio increased (1,336 drugs)

Browse all the conditions that are associated with International normalised ratio increased:

International normalised ratio increased (1,727 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eptifibatide (the active ingredients of Integrilin) and Integrilin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.